Novartis eyecare subsidiary Alcon has agreed to acquire the Institut Mérieux, Ascension Health and MemorialCare Health System-backed MIGS technology provider.
Alcon, a vision care subsidiary of pharmaceutical group Novartis, agreed on Monday to acquire Ivantis, a US-based, corporate-backed minimally invasive glaucoma surgery (MIGS) technology provider, for $475m.
The deal could be boosted by potential regulatory and commercial milestone payments, and is expected to close by the end of the first quarter of 2022.
Ivantis provides a device called Hydrus Microstent which is designed to help ophthalmic surgeons conduct MIGS procedures to treat glaucoma, which is caused by increased pressure in…
